FDA warns Premium Health over misleading website claims for compounded semaglutide and tirzepatide.
What happened
FDA reviewed Premium Health's website in December 2025 and found it offered compounded semaglutide and tirzepatide drug products. FDA said the site's labels implied Premium Health was the compounder when it was not, and claims such as "generic compounded medication" implied FDA approval or evaluation. FDA cited these as false or misleading and therefore misbranded.
What FDA found
Website labels showed Premium Health as the compounder even though it is not, making the products misbranded.
FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]; 21 CFR § 201.1(h)(2)Claims like "generic compounded medication" and references to active ingredients in Ozempic, Wegovy, and Mounjaro implied FDA approval or evaluation when compounded drugs are not FDA-approved.
FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The misbranded products were introduced or delivered for introduction into interstate commerce.
FDCA § 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA asks Premium Health to respond within 15 working days describing steps taken to correct the violations, including identifying who produces the compounded products, providing sample labeling, and addressing or removing misleading website claims.
Who should pay attention
- telehealth companies selling compounded GLP-1 drugs
- compounding pharmacies whose products are promoted by marketers
- legal and regulatory teams reviewing drug promotional claims
This is a summary. Read the original letter on fda.gov.